{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/impetigo/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"46b7f694-9523-5232-ad5d-ca6d1dba2c94","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field ca829abd-10f6-43f7-b3c6-e207f7708885 --><h2>How should I assess a person with suspected impetigo?</h2><!-- end field ca829abd-10f6-43f7-b3c6-e207f7708885 -->","summary":"","htmlStringContent":"<!-- begin item 63504d20-067b-48a2-90f3-d1f49a40ce2b --><!-- begin field 08e97208-3e6c-44c0-b24e-ba8211412999 --><ul><li><strong>Take a history asking about:</strong><ul><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/impetigo/diagnosis/clinical-features/\">clinical features</a> of impetigo including onset, evolution, duration and location of lesions.</li><li>Contacts with a similar rash.</li><li>Past medical history including pre-existing skin conditions (such as eczema) or immunosuppression.</li><li>Other risk factors for impetigo such as trauma to the skin (for example, abrasions or insect bites).</li><li>Previous treatment including antimicrobial therapy.</li><li>Systemic features such as fever.</li></ul></li><li><strong>Examine the person looking for:</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/impetigo/diagnosis/clinical-features/\">Clinical features</a> of impetigo such as bullae or yellow exudate forming a crust.</li><li>Features of systemic involvement such as lymphadenopathy or fever.</li><li>Signs of <a class=\"topic-reference internal-reference\" href=\"/topics/impetigo/diagnosis/differential-diagnosis/\">conditions that may present similarly</a> to impetigo.</li></ul></li><li><strong>Consider the need for investigations:</strong><ul><li>Impetigo is usually a clinical diagnosis and investigations are not needed.</li><li>Swabs (of exudate from a moist lesion or de-roofed blister) for culture and sensitivities should be considered in cases which are persistent despite treatment, recurrent, or widespread.<ul><li>The possibility of meticillin-resistant <em>Staphylococcus aureus</em> (MRSA) should be considered.</li></ul></li></ul></li></ul><!-- end field 08e97208-3e6c-44c0-b24e-ba8211412999 --><!-- end item 63504d20-067b-48a2-90f3-d1f49a40ce2b -->","topic":{"id":"df142ae3-a675-5faa-955f-deba3aa176bc","topicId":"08c2a82c-2e88-477a-a00d-e75b47770e61","topicName":"Impetigo","slug":"impetigo","lastRevised":"Last revised in February 2020","chapters":[{"id":"5d5b7bff-ba78-5008-89df-49963bc208b7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"35862574-df78-5554-bbe6-86275287ef3a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc13ef99-c08d-5361-89de-765433a18ce3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8abd7c1c-e4d5-5fc6-9deb-2cfbbee04b6a","slug":"changes","fullItemName":"Changes"},{"id":"5105f48d-40d4-5c74-bec6-af0574471e5a","slug":"update","fullItemName":"Update"}]},{"id":"8c2bfe64-9ced-531b-b641-00b4ff18bd7c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"eaefc2a4-19e1-525e-82f4-dccc7115b2b6","slug":"goals","fullItemName":"Goals"},{"id":"5a84c42b-0cca-52ed-9924-c54417494c01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5275b616-56f0-5b49-b2df-0cbffee7e3fc","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6ed2c217-68c2-5ecc-8c61-7187fcbead1b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1dec750c-6e33-5adf-ae33-87a7f4a042c2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"abff03ac-c7cc-5fe7-b6de-0871e4a2846a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba37e0a2-65cd-52ec-8992-3299b96c1ea0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9440ce15-e09d-57c4-9ff1-70e323defaf3","slug":"definition","fullItemName":"Definition"},{"id":"605ba802-106d-5b36-93df-7644ebd9231d","slug":"causes","fullItemName":"Causes"},{"id":"863740f1-ab66-5109-bcb1-30ef774d0d2c","slug":"incidence","fullItemName":"Incidence"},{"id":"69d86930-4301-54ce-8d47-133d348f0b7b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"afe26e4f-1499-57be-a412-9d17510303e9","slug":"complications","fullItemName":"Complications"}]},{"id":"cf492669-e436-53c8-b2b7-f369198b6622","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8dee3a55-eaa2-5aab-b6e5-9a89ad394715","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"46b7f694-9523-5232-ad5d-ca6d1dba2c94","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6e579521-48f9-59b3-a8e3-5e8e37473653","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eebe4528-d9d4-5e2e-ab08-fe1255e1564b","fullItemName":"Management","slug":"management","subChapters":[{"id":"3f2b5528-3a31-51ee-9a7c-713b86cf2854","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"60f683cb-4447-5ecd-9b90-245b33e20336","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f5f53214-ec8d-5ca7-8dde-0ef07d26b140","slug":"hydrogen-peroxide","fullItemName":"Hydrogen peroxide"},{"id":"178eb388-927e-59ea-8289-59bd71cf7ae0","slug":"fusidic-acid","fullItemName":"Fusidic acid"},{"id":"7ee4e706-9719-555b-85eb-18477604621b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"58ff6676-3c7d-5610-98c3-5e6b6b326c5c","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"9983753e-f306-528c-bcad-5c5e37e49831","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4825af9d-eb38-5c45-a29d-40a17e11e044","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"484c3649-34b0-537b-9431-0907ac172480","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e05d1269-8a31-569f-b89a-f9609763db8b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c7093c62-22f3-531b-ab5c-3c222fd9220e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25fc1ec7-3a38-5636-9e71-37951cbae3e8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7eec7c7-f55f-53ec-afb1-6fa00707cb90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9e2f110a-ec9f-5728-8f52-cb51f2bfe209","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cf492669-e436-53c8-b2b7-f369198b6622","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"a2c43e9f-8fc5-56ec-8cb9-033621a1ccd0","slug":"basis-for-recommendation-6b2","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 3662145e-e173-4b62-b583-042efb6f66ff --><h3>Basis for recommendation</h3><!-- end field 3662145e-e173-4b62-b583-042efb6f66ff -->","summary":null,"htmlStringContent":"<!-- begin item 6b23f183-69f2-4e7f-8e78-d961821bafc7 --><!-- begin field a25c8f48-9904-4de3-a7a1-7ed404214ab5 --><p>The recommendations on the assessment of impetigo are based on the clinical guidelines <em>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Stevens, 2014</a>], <em>Impetigo </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">PCDS, 2018</a>] and <em>Health protection in schools and other childcare facilities. A practical guide for staff on managing cases of infectious diseases in schools and other childcare settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">PHE, 2018</a>], the Canadian clinical effectiveness review <em>Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">CADTH, 2017</a>], Rooks textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Hay, 2016</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Hartman-Adams, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Lawton, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Allmon, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">McClain, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BMJ Best Practice, 2018</a>].</p><!-- end field a25c8f48-9904-4de3-a7a1-7ed404214ab5 --><!-- end item 6b23f183-69f2-4e7f-8e78-d961821bafc7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}